Effect of atorvastatin on subclinical atherosclerosis in virally-suppressed HIV-infected patients with CMV seropositivity: a randomized double-blind placebo-controlled trial
Open Access
- 26 February 2021
- journal article
- research article
- Published by F1000 Research Ltd in F1000Research
- Vol. 10, 151
Abstract
Background: Persistent immune activation and inflammation in HIV-infection are linked to excess cardiovascular risk and other non-communicable diseases. Periodic asymptomatic CMV-reactivity in HIV infected patients over a lifetime may contribute to non-AIDS defining morbidity. Despite undetectable levels of HIV and CMV, these patients continue to have increased levels of biomarkers and immune activations. Statin administration is thought to reduce subclinical atherosclerosis by decreasing LDL-C levels. It may also add beneficial effects against CMV infection. Methods: We are conducting a double-blind placebo-controlled trial in which patients are randomized to receive either atorvastatin or placebo with a ratio of 1:1. This trial aims to study the effect of atorvastatin in statin-naive virally-suppressed HIV-infected patients with stable ART and CMV seropositivity on carotid intima media thickness (CIMT), tool that evaluates subclinical atherosclerosis. The study recruits 80 patients at HIV integrated care unit of Cipto Mangunkusumo hospital. All eligible subjects have CIMT evaluation as primary outcome, along with flow mediated vasodilatation (FMD), liver fibrosis and steatosis evaluation, fasting lipid, neurocognitive test, community periodontal index (CPI), and residual immune activation as secondary outcomes in 48 weeks. Ethics and dissemination: This study has received an ethical approval from Health Research Ethics Commitee–Universitas Indonesia and Cipto Mangunkusumo Hospital. Before joining the study, all participants fill in an informed consent form. At the end of study analysis, the trial results will be published and disseminated in peer-reviewed journals. Discussion: The main purpose of our study is to evaluate the effect of atorvastatin administration on CIMT changes in statin naïve virally suppressed HIV-infected patients with stable ART and CMV seropositivity Registration: ClinicalTrials.gov ID NCT04101136; registered on 24 September 2019.Keywords
Funding Information
- Kementerian Riset Teknologi Dan Pendidikan Tinggi Republik Indonesia (173/SP2H)
This publication has 37 references indexed in Scilit:
- Indices for measuring periodontitis: a literature reviewInternational Dental Journal, 2020
- Medication possession ratio: implications of using fixed and variable observation periods in assessing adherence with disease-modifying drugs in patients with multiple sclerosisPatient Preference and Adherence, 2013
- Cytomegalovirus Immunoglobulin G Antibody Is Associated With Subclinical Carotid Artery Disease Among HIV-Infected WomenThe Journal of Infectious Diseases, 2012
- Assessment of flow-mediated dilation in humans: a methodological and physiological guidelineAmerican Journal of Physiology-Heart and Circulatory Physiology, 2011
- 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic AdultsJACC, 2010
- Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapyAIDS, 2010
- Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patientsAIDS, 2009
- Endothelial Function in Human Immunodeficiency Virus-Infected Antiretroviral-Naive Subjects Before and After Starting Potent Antiretroviral TherapyJACC, 2008
- Inflammation, Atherosclerosis, and Coronary Artery DiseaseNew England Journal of Medicine, 2005
- Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial arteryJACC, 2002